Drugs / PRT811
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04089449 | Nov 2019 → Mar 2023 | glioma | Prelude Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Prelude Therapeutics | Results Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics preludetx.com ↗
We are also encouraged by the preliminary clinical activity observed with both molecules in multiple tumor types, including durable responses in cancers with high unmet need. |
| 2020-11-10 | Prelude Therapeutics | Results Prelude Therapeutics Announces Third Quarter 2020 Financial Results preludetx.com ↗
Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-10-07 | Prelude Therapeutics | Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics preludetx.com ↗ |
| 2020-11-10 | Prelude Therapeutics | Prelude Therapeutics Announces Third Quarter 2020 Financial Results preludetx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT811 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04089449 ↗ |
| Action | Inhibit | “PRMT5 inhibitor” NCT04089449 ↗ |
| Route | Oral | “PRT811 will be administered orally” NCT04089449 ↗ |
| Target | PRMT5 | “PRMT5 inhibitor” NCT04089449 ↗ |